Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in moderate to severe atopic dermatitis
NL-OMON48825Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in atopic dermatitis (AD) (3 arms), sponsored by AbbVie Inc. Primary endpoints: vIGA-AD 0 or 1 with at least 2-grade reduction at Week 16 and EASI 75 at Week 16. Started Jan 2019; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON48825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48825.